Owkin, Genmab A/S to explore cancer patient profiles for treatment improvements
Today, Owkin announced a research agreement with Genmab A/S (Nasdaq: GMAB), an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics to fight against cancer and other serious diseases, to better understand the complex biological profiles of cancer patients.
Owkin will apply state-of-the-art machine learning to multimodal patient data, accessed through their federated research network of leading academic centers and medical experts to improve patient outcomes by analysing certain patient subgroups’ response to treatments in an effort to evaluate the medical impact of Genmab’s clinical assets, including trial design and patient selection.
The research agreement will focus on patients diagnosed with certain types of cancers.
Financial terms are not disclosed but include an upfront payment and R&D funding.
About Owkin
Owkin is an AI company on a mission to solve the complexity of biology. It is building the first Biology Super Intelligence (BASI) by combining powerful biological large language models, multimodal patient data, and agentic software. At the heart of this system is Owkin K, an AI copilot and its new LLM finetuned on biology called Owkin Zero, used by researchers, clinicians, and drug developers to better understand biology, validate scientific hypotheses, and deliver better diagnostics and therapies faster.
